Reaction
Lung Carcinoma Cell Type Unspecified Recurrent reporting signals
As of the last recalculation, Lung Carcinoma Cell Type Unspecified Recurrent appears in 607 FAERS reports alongside 9 co-occurring drug terms. The strongest observed disproportionality signal is GEFITINIB (PRR 70.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Gefitinib | 18 | 70.4 | 70.6 |
| Osimertinib | 29 | 32.5 | 32.6 |
| Erlotinib | 8 | 28.7 | 28.7 |
| Umeclidinium | 6 | 23.2 | 23.2 |
| Erlotinib Hydrochloride | 8 | 22.2 | 22.2 |
| Durvalumab | 10 | 17.1 | 17.1 |
| Ado-Trastuzumab Emtansine | 4 | 16.4 | 16.4 |
| Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate | 12 | 10.1 | 10.1 |
| Trifluridine And Tipiracil | 3 | 9.6 | 9.6 |